Lutonix™ 10 years anniversary in Europe
The voice of the thought leaders
Interview Video Series
More than a decade ago, we have seen the evolution of superficial femoral arterial care, the drug coated balloon paradigm shift.
When we look back, the field was young, physicians needed data from large, randomized controlled clinical trials that are independently validated. LEVANT was one of the pioneer studies....
Prof. Scheinert Interview Video
“LEVANT trial was certainly one of the most exciting scientific projects I have been involved with. The technology of drug coated balloon was absolutely new to the field. Everybody was really excited about this new option.....”
Prof. Brodmann & Dr. Lichtenberg Interview Video
“It’s really a long time when I hear this, but it is 10 years already. Time pass by so quickly. I can still remember when we involved in this first trial. We were very excited because we were the first drug coated DCB trials on the market...”
Dr. Manzi Interview Video
“Lutonix™ 035 balloon was the first FDA approved DCB. This should be enough to understand the importance of the background of the drug coated (technology), so all the paper and the study, preclinical studies perform, for sure among the numerous papers and trials.
The LEVANT 2 study published on New England Journal of Medicine is an excellent, high quality Randomized Controlled Trial, and this trial demonstrating optimal results......”
Dr. Cioppa Interview Video
“I think that the introduction of DCB technology has tremendously changed in the treatment of PAD and in particular, the femoro-popliteal and BTK lesions. I’m an interventional cardiologist and I already have seen the excellent results of drug-eluting technology in the treatment of coronary lesions. For this reason, in our cath lab, we immediately decided to treat almost of the femoral-popliteal and BTK lesions with DCB and the results are very positive both in terms of patency and in terms of stent implantation reduction...”
Register to have access to the Lutonix™ resources
